It is a link for moving within the page.
Go to the main.
Go to the global navigation.
Go to navigation by category.
Go to the footer.
Otsuka Pharmaceutical Co., Ltd.
Menu
Pharmaceutical Business
Nutraceutical Business
For patients & caregivers
Careers
Product FAQs
Contact Us
Our Two Core Businesses and Products
Health & Illness
Innovation & Science
CSR
About Otsuka
Philosophy
Previous
Next
Close
Our Two Core Businesses and Products
TOP
Product Development Stories
Otsuka Stories
Our Products
Health & Illness
TOP
Protect Yourself From Heat Disorders
Preventing Traveller's Thrombosis (Economy Class Syndrome)
Living well with menopause
The surprising facts about dietary fiber
Everything You Need to Know about GI
Jump start your brain with a well-balanced breakfast
Vitamins & Minerals Q&A
BCAA Helps Maintain Exercise Performance
Parkinson's Disease
Restless Legs Syndrome
Learn about Heart Failure, its Prevention, and Treatment
PAD: Be Careful of Changes in Your Limbs
Liver cirrhosis nutritional therapy
Get Your Healthy Stomach Back
Tuberculosis - An Old Disease with a New Face
Did You Know There Are Quick Tests for Infectious Diseases?
Do You Have Symptoms of Dry Eye?
Acne: Are You Doing Anything About It?
Menopause lab (Japanese)
Lactic acid bacterium B240 lab (Japanese)
AMP helps the renewal of skin cells (Japanese)
Sleep Rhythm Lab (Japanese)
Smile Navigator: Schizophrenia (Japanese)
Smile Navigator: Bipolar disorder (Japanese)
Smile Navigator: Depression (Japanese)
Smile Navigator: Pediatric autism spectrum disorder (Japanese)
Gen-shu.jp ("reducing alcohol consumption", in Japanese only)
ADPKD.JP (Japanese)
Decoboco eye: All about eye health (Japanese)
Innovation & Science
TOP
Original Research & Development
Principal Research & Development Facilities
Pipeline
Otsuka’s Open Innovation
Clinical Trial Data Transparency
Partnering/Licensing Activities
CSR
TOP
Health
Environment
Quality
Culture
Employees
Related Information
About Otsuka
TOP
Message from Top Management
Corporate Philosophy
Otsuka People Talk
Corporate Profile
Financial Performance
Timeline of Otsuka’s History
Contact Addresses in Japan
Affiliated Companies
Production Activities
Original Global Development
Business and R&D Collaborators
Corporate Governance
News Releases
Global Topics Whats & Whos
Notices
Philosophy
TOP
Corporate Symbol
Three Monuments
Corporate
Philosophy
日本語
Site search
Close
HOME
About Otsuka
News Releases
News releases related to tuberculosis
News Releases
News releases related to tuberculosis
View by year
2020
2018
2017
2016
2015
2014
2013
2012
2011
2020
25 MAY 2020
Pharmaceuticals
Deltyba
®
(delamanid) approved in Russian Federation for treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB)
27 FEB 2020
Pharmaceuticals
First-of-its-kind global collaboration launched to develop transformative treatment regimens for tuberculosis
2018
23 MAR 2018
Pharmaceuticals
Otsuka's DELTYBA Approved in China for the Treatment of Multidrug-resistant Tuberculosis
29 JAN 2018
Pharmaceuticals
Otsuka Awarded Grant to Advance Development of Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid
2017
14 DEC 2017
Pharmaceuticals
Otsuka Pharmaceutical Co., Ltd. Receives the Japan Medical R&D Grand Prize for Development of Delamanid, a Drug for Multidrug-resistant Tuberculosis Japanese Government Grants Award for the First Time
24 AUG 2017
Pharmaceuticals
Otsuka and Mylan Announce License Agreement to Commercialize Delamanid (DeltybaTM) for Multidrug-Resistant Tuberculosis (MDR-TB) in High-Burden Countries (PDF:467.1 KB)
18 JUL 2017
Pharmaceuticals
Otsuka and R-Pharm Announce Licensing Agreement to Commercialize DeltybaTM (Delamanid) for Multidrug-Resistant Tuberculosis (MDR-TB) in Russia and CIS Countries (PDF:99.9 KB)
1 JUN 2017
Pharmaceuticals
Otsuka to Continue Commitment to Support the Global Health Innovative Technology Fund (GHIT Fund)
2016
21 APR 2016
Pharmaceuticals
Otsuka receives two commendations by the Japanese Government for the development of an anti-tuberculosis agent and an aquaretic/ADPKD treatment
25 FEB 2016
Pharmaceuticals
Otsuka Announces Worldwide Access Plan for Delamanid with Stop TB Partnership's Global Drug Facility
2015
7 DEC 2015
Pharmaceuticals
Winner Announced for the 2015 Young Innovator in TB Research Award
16 JUL 2015
Pharmaceuticals
Efficacy Results of Otsuka's Delamanid (Deltyba
™
) for Extensively Drug-Resistant Tuberculosis (XDR-TB) Published in the New England Journal of Medicine
19 MAR 2015
Pharmaceuticals
The Union and Otsuka Open Nominations for 2
nd
Global TB Research & Innovation Award
2014
8 SEP 2014
Pharmaceuticals
A Change in the Treatment of Multidrug-Resistant Tuberculosis Begins New Antituberculosis Drug Deltyba
®
in 50 mg Tablets, Available to Patients in Japan Starting September 26
4 JUL 2014
Pharmaceuticals
After 40 Years, A New Drug For The Treatment Of Tuberculosis In Japan
Deltyba
®
(delamanid) Is The First Drug Approved In Japan Specifically For Pulmonary Multidrug-Resistant Tuberculosis (MDR-TB)
30 APR 2014
Pharmaceuticals
Otsuka Wins European Marketing Authorization for Deltyba
™
(delamanid)
2013
25 NOV 2013
Pharmaceuticals
CHMP Recommends Otsuka's Deltyba
™
(delamanid) for EU Approval for Treatment of Multidrug-Resistant Tuberculosis (MDR-TB) in Combination with Optimized Background Regimen (OBR)
27 MAR 2013
Pharmaceuticals
Otsuka's Novel Treatment for Multidrug-Resistant Tuberculosis, Delamanid, Submitted For Regulatory Approval in Japan -- Half Century Since Last Drug Was Approved in Japan for Tuberculosis
2012
7 JUN 2012
Pharmaceuticals
The New England Journal of Medicine Publishes Efficacy Results of Otsuka's Delamanid for Multidrug-Resistant Tuberculosis New Research Shows 53% Increase in Sputum Culture Conversion (SCC) After Two Months
2011
17 MAY 2011
Pharmaceuticals
Otsuka Pharmaceutical Establishes Subsidiary, Otsuka SA, to Facilitate Public Advocacy for the Company's Global Tuberculosis Program